source
- Vaderis fuels up with $152M series B to test rare vascular disease in Phase 3Vaderis is hoping that engasertib will become the first approved medicine for hereditary hemorrhagic telangiectasia, a rare condition that can cause spontaneous bleeding.BioSpace · 3h ago↗ source
- STAT+: Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate?Biotech companies don’t hide or obfuscate strong data.STAT · 6h ago↗ source
- Scribe Therapeutics launches first gene‑editing IPO in over two years, targeting high‑cholesterol geneScribe Therapeutics, a gene‑editing biotech based in California, announced its initial public offering, the first for a CRISPR‑focused company in more than two years. The company, founded by resea…